Sun Pharma’s allround growth can fuel stock
Synopsis
The outperformance was driven by a strong showing across all segments (except active ingredients) over the year-ago June quarter and over the preceding March quarter. Gains were made by the US specialty business, there was recovery in the branded generic portfolio in India besides some benefit from Covid-related drugs.
ET Intelligence Group: India’s largest pharma company reported a remarkable performance in the first quarter of this fiscal — satisfying investors who have been waiting to see the company deliver a strong show. The evidence was the 10% jump in the stock following the announcement of results on Friday.
The outperformance was driven by a strong showing across all segments (except active ingredients) over the year-ago June quarter and over the
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Get Offer
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.